Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00344708
Recruitment Status :
(Potential subjects did not meet eligibility criteria)
First Posted : June 27, 2006
Last Update Posted : August 22, 2018
University of Texas Southwestern Medical Center
Information provided by (Responsible Party):
James McCulley, University of Texas Southwestern Medical Center
To investigate the effect of using tissue cultured human amniotic epithelial cells to re-establish severely damaged ocular surfaces. Specifically, to determine the efficacy of transplanted tissue cultured amniotic epithelial cells on persistent corneal epithelial defect, a potential visual threaten ocular disorder.
Condition or disease
Corneal Epithelial Dystrophy
Procedure: Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells
Ocular surface diseases and injury caused by chemicals, result in chronic ulceration, and may never be able to be healed normally, and may lead to permanent vision loss. Standard medical treatments often fail. Histologically and somehow functionally, human amniotic cells are similar to ocular surface cells, and these cells have been shown to be safe to be transplanted to another subject and will not be rejected by the recipient. In animal studies, amniotic cells demonstrated that they can re-establish the integrity of ocular surface in more than 30% of recipients without apparent toxic side effects. This study will investigate this novel strategy for its effect on human ocular surface disorder. It will provide a potential alternative therapy for this difficult and devastating disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 88 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with corneal epithelial defects and ulcers that have persisted for 4 weeks or longer, regardless of their cause. These patients will have received traditional medical therapy, including correcting the underlying causes, suppressing inflammation, and augmenting the tissue healing processes, but the epithelial defects have persisted.
Patients who are pregnant or under age 18 will be excluded.
Placentas will not be used if the following problems are present:
If the mother has an infection at the time of her baby's birth;
If the mother has a high risk of developing infection due to intravenous drug use or other factors;
If the mother has diabetes, arthritis, or raised blood pressure;
If the baby is unhealthy;
If there is evidence of infection of the womb (uterus) and afterbirth (placenta) at the time of delivery.